Πλοήγηση ανά Συγγραφέα "Luo S., Vasbinder A., Du-Fay-de-lavallaz J.M., Gomez J.M.D., Suboc T., Anderson E., Tekumulla A., Shadid H., Berlin H., Pan M., Azam T.U., Khaleel I., Padalia K., Meloche C., O’hayer P., Catalan T., Blakely P., Launius C., Amadi K.-M., Pop-Busui R., Loosen S.H., Chalkias A., Tacke F., Giamarellos-Bourboulis E.J., Altintas I., Eugen-Olsen J., Williams K.A., Volgman A.S., Reiser J., Hayek S.S., on behalf of the ISIC (International Study of Inflammation in COVID-19) Group"

Αποτελέσματα 1-1 από 1

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19

Luo S., Vasbinder A., Du-Fay-de-lavallaz J.M., Gomez J.M.D., Suboc T., Anderson E., Tekumulla A., Shadid H., Berlin H., Pan M., Azam T.U., Khaleel I., Padalia K., Meloche C., O’hayer P., Catalan T., Blakely P., Launius C., Amadi K.-M., Pop-Busui R., Loosen S.H., Chalkias A., Tacke F., Giamarellos-Bourboulis E.J., Altintas I., Eugen-Olsen J., Williams K.A., Volgman A.S., Reiser J., Hayek S.S., on behalf of the ISIC (International Study of Inflammation in COVID-19) Group (2022)

BACKGROUND: Venous thromboembolism (VTE) contributes significantly to COVID-19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen ...